一项试点研究评估中点康胺度,以估计药理动力学和曲线下的面积:一项前性研究
Aseel AbuSara1, Deema Abdelrahman2, Wedad Awad2
1Department of Pharmacy, King Hussein Cancer Center, P.O.Box 1269, Queen Rania Al-Abdallah Street, Amman, 11941, Jordan. aa.10074@KHCC.JO.
BMC infectious diseases
|September 27, 2025
概括
在重症癌症患者中使用单个中点度监测胺水平,为传统的两级监测提供了潜在的成本效益替代方案. 这种方法准确地估计了关键的药理动力学参数,如AUC24,Vd和Cl.
科学领域:
- 药理动力学 药理动力学
- 临床药房 临床药房
- 关键护理医学 关键护理医学
背景情况:
- 目前的指导方针建议通过曲线下的面积 (AUC24) 通过峰值和低谷水平监测科米辛,通常使用贝叶斯软件.
- 这种传统方法在所有临床环境中可能不是可行的或具有成本效益.
- 评估替代性,更简单的监测策略对于优化万科米辛治疗至关重要.
研究的目的:
- 评估使用单个中点度估计万科米辛在曲线下的面积 (AUC24) 的准确性和精度.
- 为了确定中点度是否可以有效地捕捉药代动力学参数,如分布体积 (Vd) 和清除量 (Cl).
- 将这些估计与使用高峰和低谷水平的既定贝叶斯方法进行比较.
主要方法:
- 一项前性研究,涉及重症癌症患者接受万科米辛治疗,功能稳定.
- 在平衡状态下测量万科米辛的最低,峰值和中点度.
- 使用单个中点的药理动力学方程计算AUC24,Cl和Vd,并与贝叶斯软件估计进行比较.
主要成果:
- 包括91名患者;77%的人患有固体瘤.
- 与贝叶斯方法相比,中点方法对AUC24 (11%,22%),Cl (17%,24%) 和Vd (6%,9%) 的准确度和精度很好.
- 在中点和贝叶斯方法之间,平均Vd和Cl值是可比的.
结论:
- 使用单个中点度估计万科米辛的药理动力学参数是一种有希望的,可能更容易获得的方法.
- 在更大,多样化的患者群体中进一步验证是有必要的,以充分建立这种方法.
- 这种简化监测可以在资源有限的环境中改善万科米辛治疗的管理.
相关概念视频
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
238
Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
238
Estimation of k and VD of Aminoglycosides
214
Aminoglycosides are a class of antibiotics used to treat various bacterial infections. Clinicians must determine the elimination rate constant (k) and volume of distribution (VD) to optimize therapeutic efficacy and minimize toxicity. The k value represents the rate at which the drug is removed from the body, and the VD reflects the degree to which the drug distributes into body tissues. Accurately estimating these parameters allows healthcare professionals to tailor drug dosing to individual...
214
Measurement of Bioavailability: Pharmacodynamic Methods
236
Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.
236
One-Compartment Open Model: Wagner-Nelson and Loo Riegelman Method for ka Estimation
1.1K
This lesson introduces two critical methods in pharmacokinetics, the Wagner-Nelson and Loo-Riegelman methods, used for estimating the absorption rate constant (ka) for drugs administered via non-intravenous routes. The Wagner-Nelson method relates ka to the plasma concentration derived from the slope of a semilog percent unabsorbed time plot. However, it is limited to drugs with one-compartment kinetics and can be impacted by factors like gastrointestinal motility or enzymatic degradation.
On...
On...
1.1K
Measurement of Bioavailability: Pharmacokinetic Methods
257
Pharmacokinetics is a vital branch of pharmacology that examines how drugs are absorbed, distributed, metabolized, and excreted by the body. Two key methodologies in pharmacokinetics are plasma drug concentration studies and urinary drug excretion analyses, both of which provide critical insights into a drug's therapeutic efficacy and bioavailability.Plasma Drug Concentration-Time StudiesPlasma drug concentration-time studies involve analyzing blood samples at specific intervals to quantify...
257
Dosage Regimens: Partial Pharmacokinetic Parameters
154
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
154


